Described as a high-conviction growth play that is currently 'dirt cheap' and significantly undervalued due to broader market sell-offs.

Viewed as a hold; guidance is lower than preferred and there is a long-term disruption risk from xenografts.

A very bullish report with a massive EPS beat sent the stock up 10%, making it a smaller-cap name to watch in the healthcare space.

Stock was up 8% after a bullish conference. It is viewed as a compelling small-cap growth story.

The stock is considered inexpensive after an 8-9% drop, which is viewed as a buying opportunity due to a predictable seasonal slowdown. The company raised its full-year revenue guidance and has a long-term goal of 10,000 transplants by 2028, potentially making it a 'multi-bagger' stock.

Used as a historical example where a stock drop caused by a letter from lawmakers proved to be a temporary setback and a buying opportunity, as the stock has since recovered and is up 50%.